Evaxion Biotech a/S Sample Contracts

REGISTRATION RIGHTS AGREEMENT
Registration Rights Agreement • December 21st, 2023 • Evaxion Biotech a/S • Biological products, (no disgnostic substances) • New York

This Registration Rights Agreement (this “Agreement”) is made and entered into as of December 18, 2023, between Evaxion Biotech A/S, a public limited liability company incorporated under the laws of the Kingdom of Denmark (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”).

AutoNDA by SimpleDocs
SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • February 5th, 2024 • Evaxion Biotech a/S • Biological products, (no disgnostic substances) • New York

This Securities Purchase Agreement (this “Agreement”), dated as of February 1, 2024, is between Evaxion Biotech A/S, a public limited liability company incorporated under the laws of the Kingdom of Denmark (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).

EVAXION BIOTECH A/S 3,428,571 American Depositary Shares Representing 3,428,571 Ordinary Shares UNDERWRITING AGREEMENT
Underwriting Agreement • November 5th, 2021 • Evaxion Biotech a/S • Biological products, (no disgnostic substances) • New York

Evaxion Biotech A/S, a company incorporated under the laws of the Kingdom of Denmark (the “Company”), proposes, subject to the terms and conditions contained herein, to sell to you and the other underwriters (the “Underwriters”) named on Schedule I to this Underwriting Agreement (the “Agreement”), for whom you are acting as Representative (the “Representative”), an aggregate of 3,428,571 American Depositary Shares (the “Firm Shares”), each representing one (1) ordinary share, DKK 1 nominal value, of the Company (the “Ordinary Shares”) (“ADSs” shall mean the American Depositary Shares of the Company, each ADS representing one (1) Ordinary Share). The respective amounts of the Firm Shares to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto. In addition, the Company proposes to grant to the Underwriters an option to purchase up to an additional 514,285 ADSs (the “Option Shares”) from the Company for the purpose of covering over-allot

REGISTRATION RIGHTS AGREEMENT
Registration Rights Agreement • June 7th, 2022 • Evaxion Biotech a/S • Biological products, (no disgnostic substances) • New York

THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of June 7, 2022, is made by and between EVAXION BIOTECH A/S, a company incorporated under the laws of the Kingdom of Denmark (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Purchase Agreement by and between the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”).

CAF®09b Supply, Patent, Know How & Trademark Licence Agreement DATED 30 NOVEMBER 2020 between - and -
Trial Supply Agreement • January 8th, 2021 • Evaxion Biotech a/S • Biological products, (no disgnostic substances)

THIS “CAF®09b SUPPLY, PATENT, KNOW HOW & TRADEMARK LICENSE AGREEMENT” (this “Agreement”) is made on the 30th of November, 2020 (the “Effective Date”)

Contract
Evaxion Biotech a/S • January 8th, 2021 • Biological products, (no disgnostic substances)

[****] This symbol identifies certain confidential information contained in this document that has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

Investment Agreement Evaxion biotech A/S
Investment Agreement • December 21st, 2023 • Evaxion Biotech a/S • Biological products, (no disgnostic substances) • New York
Contract
Evaxion Biotech a/S • August 4th, 2023 • Biological products, (no disgnostic substances)
PURCHASE AGREEMENT
Purchase Agreement • June 7th, 2022 • Evaxion Biotech a/S • Biological products, (no disgnostic substances)

THIS PURCHASE AGREEMENT (the “Agreement”), dated as of June 7, 2022, is made by and between EVAXION BIOTECH A/S, a company incorporated under the laws of the Kingdom of Denmark (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”). Capitalized terms used herein and not otherwise defined herein are defined in Section 1 hereof.

STRICTLY CONFIDENTIAL Evaxion Biotech A/S Dr. Neergaards Vej SF
Letter Agreement • January 31st, 2024 • Evaxion Biotech a/S • Biological products, (no disgnostic substances) • New York
= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED Clinical Trial Collaboration and Supply Agreement by and between MSD...
Clinical Trial Collaboration and Supply Agreement • October 25th, 2021 • Evaxion Biotech a/S • Biological products, (no disgnostic substances) • New York

This Clinical Trial Collaboration and Supply Agreement is entered into as of the Effective Date, by and among MSD International GmbH (“MSDIG”), MSD International Business GmbH (“MSDIB” and, collectively with MSDIG, “MSD”), [***]and Collaborator (as defined below), having a place of business at the Collaborator Address (as defined below). MSD and Collaborator are each referred to herein individually as a “Party” and collectively as the “Parties”.

SECURITIES PURCHASE AGREEMENT (For US Investors)
Securities Purchase Agreement • December 21st, 2023 • Evaxion Biotech a/S • Biological products, (no disgnostic substances) • New York

This Securities Purchase Agreement (this “Agreement”), dated as of December 18, 2023, between Evaxion Biotech A/S, a public limited liability company incorporated under the laws of the Kingdom of Denmark (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).

STRICTLY CONFIDENTIAL Evaxion Biotech A/S Dr. Neergaards Vej SF
Letter Agreement • January 31st, 2024 • Evaxion Biotech a/S • Biological products, (no disgnostic substances) • New York
Time is Money Join Law Insider Premium to draft better contracts faster.